Burosumab
ENSKRN23.1
Phase 3 mab completed
Quick answer
Burosumab for Hypophosphatemia is a Phase 3 program (mab) at Ultragenyx UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx UK Limited
- Indication
- Hypophosphatemia
- Phase
- Phase 3
- Modality
- mab
- Status
- completed